PROCESS DEVELOPMENT AGREEMENT ACCORDION PILL™ CARBIDOPA LEVODOPAProcess Development Agreement • February 27th, 2019 • Intec Pharma Ltd. • Pharmaceutical preparations
[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.
AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • June 16th, 2021 • Context Therapeutics Inc. • Pharmaceutical preparations
This AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT (this “Amendment”) is effective as of this 3rd day of June, 2021 (the “Amendment Effective Date”), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at 3728 Jinke Road, Building 1 West Wing, ZhangJiang Hitech Park, Shanghai, China (“Tyligand”) and Context Therapeutics LLC, a Delaware limited liability company having its registered office at 3675 Market Street, Suite 200, Philadelphia, PA 19104 (“Context”). Tyligand and Context are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY AMENDMENT NO. 1 TO PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • May 27th, 2021 • Context Therapeutics Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO PROCESS DEVELOPMENT AGREEMENT (this “Amendment”) is effective as of this 21st day of April, 2021 (the “Amendment Effective Date”), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at 3728 Jinke Road, Building 1 West Wing, ZhangJiang Hitech Park, Shanghai, China (“Tyligand”) and Context Therapeutics LLC, a Delaware limited liability company having its registered office at 3675 Market Street, Suite 200, Philadelphia, PA 19104 (“Context”). Tyligand and Context are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • April 17th, 2007 • Biodelivery Sciences International Inc • Pharmaceutical preparations
BioDelivery Sciences International, Inc., a corporation organized and existing under the laws of Delaware, having a principal place of business at 2501 Aerial Center Parkway, Suite 205 , Morrisville, NC 27560, U.S.A. (herein after called “BDSI”); and
PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • March 20th, 2009 • Biodelivery Sciences International Inc • Pharmaceutical preparations
BioDelivery Sciences International, Inc., a corporation organized and existing under the laws of Delaware, having a principal place of business at 801 Corporate Center Drive, Suite 210, Raleigh, NC 27607, U.S.A. (herein after called “BDSI”); and
CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • May 27th, 2021 • Context Therapeutics Inc. • Pharmaceutical preparations • New York
This PROCESS DEVELOPMENT AGREEMENT (“Agreement”) is made on this 6th day of March, 2020 (“Effective Date”) by and between Context Therapeutics LLC, a Delaware limited liability company having its registered office at 3675 Market Street, Suite 200, Philadelphia, PA 19104(“Context”); and Tyligand Bioscience (Shanghai) Limited, A having its registered office at 781 Cailun Road, ZhangJiang Hitech Park, Shanghai. China (“Tyligand”). Context and Tyligand may be referred to individually as a “Party” or jointly as “Parties”.
Amendment and Restatement of (effective as of December 28, 2002) between INTERNATIONAL BUSINESS MACHINES CORP. And ADVANCED MICRO DEVICES, INC.Process Development Agreement • November 4th, 2004 • Advanced Micro Devices Inc • Semiconductors & related devices • New York
This Agreement is made effective as of the 28th day of December, 2002 (hereinafter referred to as the “Effective Date”) by and between International Business Machines Corporation (“IBM”), incorporated under the laws of the State of New York, U.S.A. and having an office for the transaction of business at 2070 Route 52, Hopewell Junction, NY 12533, U.S.A, and Advanced Micro Devices having an office for the transaction of business at One AMD Place, P.O. Box 3453, Sunnyvale, CA 94088-3453 “(AMD)”. IBM, and AMD may be individually referred to herein as a “Party,” or collectively as the “Parties.”
PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • August 28th, 2006 • Immunogen Inc • Pharmaceutical preparations • California
THIS PROCESS DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of the 3rd day of May, 2006 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation with an office at 1 DNA Way, South San Francisco, California 94080-4990 (“Genentech”), and ImmunoGen, Inc., a Massachusetts corporation with corporate headquarters at 128 Sidney Street, Cambridge, MA 02139 (“ImmunoGen”). In this Agreement, Genentech and ImmunoGen each may be referred to individually as a “Party” and together as the “Parties.”
